ID   OV90D-6
AC   CVCL_4Z25
DR   cancercelllines; CVCL_4Z25
DR   Wikidata; Q54936908
RX   PubMed=22141344;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene fusion; HGNC; 1790; CDKN2D + HGNC; 20482; WDFY2; Name(s)=CDKN2D-WDFY2 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7700; Ovarian adenocarcinoma
DI   ORDO; Orphanet_213504; Adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3768 ! OV-90
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 14
//
RX   PubMed=22141344; DOI=10.1186/1757-2215-4-21;
RA   Sherman-Baust C.A., Becker K.G., Wood W.H. III, Zhang Y.-Q., Morin P.J.;
RT   "Gene expression and pathway analysis of ovarian cancer cells selected
RT   for resistance to cisplatin, paclitaxel, or doxorubicin.";
RL   J. Ovarian Res. 4:21.1-21.11(2011).
//